Jill S. Goldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jill S. Goldman has a total of 333 co-authors. Here are the top co-authors by number of shared publications:
- Wendy R. Uhlmann
University of Michigan
6 shared publications Richard Mayeux
Department of Nephrology, Sergievsky Center and Taub Institute for Research on Alzheimer Disease and the Aging Brain, Columbia University, New York City, NY, USA
5 shared publicationsBruce L. Miller
4 shared publications- Jamie C. Fong
Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
4 shared publications - Laynie Dratch
Penn Frontotemporal Degeneration Center, Department of Neurology, School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
4 shared publications Edward D. Huey
Columbia University Medical Center
3 shared publications
Latest Publications
- 4 July 2026
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- p. 1-12
Reduced penetrance in genetic ALS/FTD spectrum disorders: implications for genetic counseling, predictive testing and treatment
As the offer of genetic testing for people with ALS/FTD becomes standard of care, clinicians and affected individuals should have accurate and balanced information regarding the clinical and familial implications of test results, including the penetrance of identified variants. Published estimates of the penetrance of specific ALS/FTD variants, including the C9orf72 repeat expansion, have varied widely. However, it is now apparent that most pathogenic variants identified in clinical testing exhibit reduced penetrance. Although data on the disease risk of many variants is limited and likely to evolve in the coming years, the challenges of estimating penetrance should not preclude transparent discussion of these issues with affected individuals and their families. Here, we review published penetrance data and highlight genetic counseling considerations to support the clinician in discussing disease risk and facilitating decision-making in genetic testing and patient care.
- 4 July 2026
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- p. 1-12
Reduced penetrance in genetic ALS/FTD spectrum disorders: implications for genetic counseling, predictive testing and treatment
As the offer of genetic testing for people with ALS/FTD becomes standard of care, clinicians and affected individuals should have accurate and balanced information regarding the clinical and familial implications of test results, including the penetrance of identified variants. Published estimates of the penetrance of specific ALS/FTD variants, including the C9orf72 repeat expansion, have varied widely. However, it is now apparent that most pathogenic variants identified in clinical testing exhibit reduced penetrance. Although data on the disease risk of many variants is limited and likely to evolve in the coming years, the challenges of estimating penetrance should not preclude transparent discussion of these issues with affected individuals and their families. Here, we review published penetrance data and highlight genetic counseling considerations to support the clinician in discussing disease risk and facilitating decision-making in genetic testing and patient care.
- 19 May 2026
- Published by Wiley in Journal of Genetic Counseling
- Vol. 35 (3) , e70226
40+ years of the Huntington disease predictive genetic testing protocol: Recommendations for an update
Guidance for predictive genetic testing for Huntington disease (HD) has been available for more than four decades and has been applied to other adult‐onset hereditary conditions, especially neurogenetic conditions. Yet this protocol has not been updated since 2016 even though there have been significant changes in healthcare delivery and policy/legal issues, including widespread use of telemedicine and new legislation impacting patients' ready access to medical records. There also have been technological advances where HD status can be revealed with genomic sequencing and societal paradigm shifts away from paternalism. Even with the well‐established components and content to cover for predictive genetic testing for HD, variability exists in how the guidance has been applied by different institutions across the United States. This variability in clinical practice can be attributed to multiple factors including institutional differences in clinical staffing, whether genetic counselors are licensed, and approaches to care. This article describes the protocol's history and how the above changes affect aspects of this guidance. Given these changes and growing availability of predictive genetic testing, we recommend an update to the 2016 Huntington Disease Society of America's (HDSA) protocol, suggest changes and offer interim practice guidance. In summary, because of changes in technology, laws, and healthcare, the Huntington disease protocol for predictive genetic testing needs to be updated. This paper offers recommendations for these changes.
- 19 May 2026
- Published by Wiley in Journal of Genetic Counseling
- Vol. 35 (3) , e70226
40+ years of the Huntington disease predictive genetic testing protocol: Recommendations for an update
Guidance for predictive genetic testing for Huntington disease (HD) has been available for more than four decades and has been applied to other adult‐onset hereditary conditions, especially neurogenetic conditions. Yet this protocol has not been updated since 2016 even though there have been significant changes in healthcare delivery and policy/legal issues, including widespread use of telemedicine and new legislation impacting patients' ready access to medical records. There also have been technological advances where HD status can be revealed with genomic sequencing and societal paradigm shifts away from paternalism. Even with the well‐established components and content to cover for predictive genetic testing for HD, variability exists in how the guidance has been applied by different institutions across the United States. This variability in clinical practice can be attributed to multiple factors including institutional differences in clinical staffing, whether genetic counselors are licensed, and approaches to care. This article describes the protocol's history and how the above changes affect aspects of this guidance. Given these changes and growing availability of predictive genetic testing, we recommend an update to the 2016 Huntington Disease Society of America's (HDSA) protocol, suggest changes and offer interim practice guidance. In summary, because of changes in technology, laws, and healthcare, the Huntington disease protocol for predictive genetic testing needs to be updated. This paper offers recommendations for these changes.
- 30 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (2) , 734-745
Exploring immediate responses to APOE ε 4/ε4 genotype and Alzheimer's disease risk disclosure in Latinos
Background: Few studies have investigated the psychosocial impact of APOE ε4/ε4 genotype disclosure, and none in ethnic minorities. Objective: We used mixed methods to investigate immediate responses to APOE ε4/ε4 genotype disclosure among Latino residents of northern Manhattan who participated in the Información de la Enfermedad de Alzheimer para Latinos (IDEAL) Study. Methods: Eleven ε4 homozygotes received their genotype and a 55% risk estimate for developing Alzheimer's disease (AD) by age 85 from bilingual genetic counselors. Session recordings were transcribed and qualitative content analysis performed. One week after disclosure, distress levels were assessed through the intrusion subscale of the Impact of Event Scale-Revised (IES-R) and five items from the Impact of Genetic Testing in AD scale (IGT-AD) for 7/11 homozygotes, compared with participants with 0 (n = 61) or 1 (n = 47) ε4 alleles who also learned their APOE genotypes. Results: Nine homozygotes were women; seven had an AD family history; age averaged 51 years. Participants with an AD family history or memory worries felt their concerns were validated; others were often surprised. Only one participant showed signs of elevated psychological distress. Responses on the IES-R intrusion subscale and IGT-AD items differed significantly from those of IDEAL participants who learned they had 0 or 1 ε4 alleles, but distress levels were low. Conclusions: Among most Latinos in northern Manhattan who learned they had an APOE ε4/ε4 genotype, disclosure did not provoke elevated levels of distress.
- 30 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (2) , 734-745
Exploring immediate responses to APOE ε 4/ε4 genotype and Alzheimer's disease risk disclosure in Latinos
Background: Few studies have investigated the psychosocial impact of APOE ε4/ε4 genotype disclosure, and none in ethnic minorities. Objective: We used mixed methods to investigate immediate responses to APOE ε4/ε4 genotype disclosure among Latino residents of northern Manhattan who participated in the Información de la Enfermedad de Alzheimer para Latinos (IDEAL) Study. Methods: Eleven ε4 homozygotes received their genotype and a 55% risk estimate for developing Alzheimer's disease (AD) by age 85 from bilingual genetic counselors. Session recordings were transcribed and qualitative content analysis performed. One week after disclosure, distress levels were assessed through the intrusion subscale of the Impact of Event Scale-Revised (IES-R) and five items from the Impact of Genetic Testing in AD scale (IGT-AD) for 7/11 homozygotes, compared with participants with 0 (n = 61) or 1 (n = 47) ε4 alleles who also learned their APOE genotypes. Results: Nine homozygotes were women; seven had an AD family history; age averaged 51 years. Participants with an AD family history or memory worries felt their concerns were validated; others were often surprised. Only one participant showed signs of elevated psychological distress. Responses on the IES-R intrusion subscale and IGT-AD items differed significantly from those of IDEAL participants who learned they had 0 or 1 ε4 alleles, but distress levels were low. Conclusions: Among most Latinos in northern Manhattan who learned they had an APOE ε4/ε4 genotype, disclosure did not provoke elevated levels of distress.
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214281
The Importance of Offering Genetic Counseling and Testing to All Persons Diagnosed With Frontotemporal Degeneration Spectrum Disorders
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214281
The Importance of Offering Genetic Counseling and Testing to All Persons Diagnosed With Frontotemporal Degeneration Spectrum Disorders
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213814
The Importance of Offering Genetic Counseling and Testing to All Persons Diagnosed With Frontotemporal Degeneration Spectrum Disorders
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213814
The Importance of Offering Genetic Counseling and Testing to All Persons Diagnosed With Frontotemporal Degeneration Spectrum Disorders
- 17 November 2023
- Published by Wiley in Movement Disorders
- Vol. 38 (12) , 2151-2154
Genetic Testing of HTT Modifiers for Huntington's Disease: Considerations for Clinical Guidelines
- 17 November 2023
- Published by Wiley in Movement Disorders
- Vol. 38 (12) , 2151-2154
Genetic Testing of HTT Modifiers for Huntington's Disease: Considerations for Clinical Guidelines
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S4)
Financial Behaviors and Experiences of Financial Loss in those with Alzheimer’s disease and Frontotemporal Dementia: Preliminary findings from a survey
Background: Older adults are increasingly experiencing financial loss, with annual costs estimated to be about $2.9 billion. The risk of experiencing financial loss is magnified in those with neurodegenerative conditions, including Alzheimer’s disease (AD) and Frontotemporal Dementia (FTD). However, limited information exists on the frequency and amount of money lost, and the behaviors that contribute to such loss in these conditions. The current study sought to characterize the nature of financial losses in AD and FTD, and to identify risk factors in an effort to prevent or mitigate financial loss.Method: Survey data were collected from ten caregivers of individuals clinically diagnosed with AD or FTD recruited via the Neurodegeneration‐Associated Psychiatric Syndromes study and caregiver support groups at Columbia University Medical Center. Survey items queried demographic information, details of financial loss, level of concerns experienced by care partners and patients, and financial behaviors resulting in financial losses (Table 1).Result: Caregivers had known the patients on average for 46 years. Out of 10 patients, 6 experienced financial loss. See Table 2 for detailed results. While the same number of patients with AD and FTD lost money, those with FTD lost money more frequently and to a larger amount than those with AD. Caregivers of FTD patients expressed a higher degree of concern relative to those with AD. Moreover, most AD patients were described as being concerned about their financial ability, as compared to none of the FTD patients having concern for their financial ability. Additionally, 3 of 5 FTD patients were reported to have engaged in repetitive spending as compared to none of the AD patients.Conclusion: Preliminary data indicate a high prevalence of financial loss (60%) in AD and FTD. The intensity of financial loss and related caregiver burden appears higher in FTD, with caregivers describing repetitive spending and less concern about difficulties, likely tied to the lack of insight which is a core feature of this disease. These findings can guide caregiver supervision and interventions to preserve family funds.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S4)
Open AccessFinancial Behaviors and Experiences of Financial Loss in those with Alzheimer’s disease and Frontotemporal Dementia: Preliminary findings from a survey
Background: Older adults are increasingly experiencing financial loss, with annual costs estimated to be about $2.9 billion. The risk of experiencing financial loss is magnified in those with neurodegenerative conditions, including Alzheimer’s disease (AD) and Frontotemporal Dementia (FTD). However, limited information exists on the frequency and amount of money lost, and the behaviors that contribute to such loss in these conditions. The current study sought to characterize the nature of financial losses in AD and FTD, and to identify risk factors in an effort to prevent or mitigate financial loss.Method: Survey data were collected from ten caregivers of individuals clinically diagnosed with AD or FTD recruited via the Neurodegeneration‐Associated Psychiatric Syndromes study and caregiver support groups at Columbia University Medical Center. Survey items queried demographic information, details of financial loss, level of concerns experienced by care partners and patients, and financial behaviors resulting in financial losses (Table 1).Result: Caregivers had known the patients on average for 46 years. Out of 10 patients, 6 experienced financial loss. See Table 2 for detailed results. While the same number of patients with AD and FTD lost money, those with FTD lost money more frequently and to a larger amount than those with AD. Caregivers of FTD patients expressed a higher degree of concern relative to those with AD. Moreover, most AD patients were described as being concerned about their financial ability, as compared to none of the FTD patients having concern for their financial ability. Additionally, 3 of 5 FTD patients were reported to have engaged in repetitive spending as compared to none of the AD patients.Conclusion: Preliminary data indicate a high prevalence of financial loss (60%) in AD and FTD. The intensity of financial loss and related caregiver burden appears higher in FTD, with caregivers describing repetitive spending and less concern about difficulties, likely tied to the lack of insight which is a core feature of this disease. These findings can guide caregiver supervision and interventions to preserve family funds.
- 1 April 2021
- Published by Wiley in Journal of Genetic Counseling
- Vol. 30 (2) , 553-562
Predictive testing for neurodegenerative diseases in the age of next-generation sequencing
The availability and cost of next-generation sequencing (NSG) now allow testing large numbers of genes simultaneously. However, the gold standard for predictive testing has been to test only for a known family mutation or confirmed family disease. The goal of this study was to investigate the psychological impact of predictive testing for autosomal dominant neurodegenerative diseases without a known family mutation using next-generation sequencing panels compared to single-gene testing of a known family mutation. Fourteen individuals from families with a known mutation and 10 individuals with unknown family mutations participated. Participants completed questionnaires on demographics, genetic knowledge, and psychological measures of anxiety, depression, perceived personal control, rumination, and intolerance to uncertainty at baseline and 1 and 6 months after receiving results. Decision regret was measured 1 and 6 months after receiving results. Participants completed a modified Huntington disease genetic testing protocol with genetic counseling and neurological and psychological evaluation. Genetic testing of either the known family mutation or an NGS panel of neurodegenerative disease genes was performed. Semi-structured interviews were performed at 6 months post-results about their experience. Two-samplettests were performed on data collected at each time point to identify significant between-group differences in demographic variables, baseline psychological scores, and baseline genetic knowledge scores. Within-group change over time was assessed by a mixed-effects model. Results of this study indicate that NGS panels for predictive testing for neurodegenerative disease are safe and beneficial to participants when performed within a modified HD protocol. Though significant differences in psychological outcomes were found, these differences may have been driven by genetic results and baseline psychological differences between individuals within the groups. Participants did not regret their decision to test and were largely pleased with the testing protocol.
- 1 April 2021
- Published by Wiley in Journal of Genetic Counseling
- Vol. 30 (2) , 553-562
Predictive testing for neurodegenerative diseases in the age of next-generation sequencing
The availability and cost of next-generation sequencing (NSG) now allow testing large numbers of genes simultaneously. However, the gold standard for predictive testing has been to test only for a known family mutation or confirmed family disease. The goal of this study was to investigate the psychological impact of predictive testing for autosomal dominant neurodegenerative diseases without a known family mutation using next-generation sequencing panels compared to single-gene testing of a known family mutation. Fourteen individuals from families with a known mutation and 10 individuals with unknown family mutations participated. Participants completed questionnaires on demographics, genetic knowledge, and psychological measures of anxiety, depression, perceived personal control, rumination, and intolerance to uncertainty at baseline and 1 and 6 months after receiving results. Decision regret was measured 1 and 6 months after receiving results. Participants completed a modified Huntington disease genetic testing protocol with genetic counseling and neurological and psychological evaluation. Genetic testing of either the known family mutation or an NGS panel of neurodegenerative disease genes was performed. Semi-structured interviews were performed at 6 months post-results about their experience. Two-samplettests were performed on data collected at each time point to identify significant between-group differences in demographic variables, baseline psychological scores, and baseline genetic knowledge scores. Within-group change over time was assessed by a mixed-effects model. Results of this study indicate that NGS panels for predictive testing for neurodegenerative disease are safe and beneficial to participants when performed within a modified HD protocol. Though significant differences in psychological outcomes were found, these differences may have been driven by genetic results and baseline psychological differences between individuals within the groups. Participants did not regret their decision to test and were largely pleased with the testing protocol.
- Open Access
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S10)
The formation of the advisory group on risk evaluation education for dementia
Background: When and how to communicate effectively the results of genetic and biomarker based prediction, detection, and quantification of the brain substrates of dementia involve important ethical and legal issues critical for precision medicine. The urgency of the issue has increased as People Living with Dementia (PLwD) and with Risk for Dementia (PwRD) can access direct to consumer genetic testing, amyloid targeting drugs, and clinical amyloid PET scans. To address the need for effective dissemination and consultation, an advisory group was convened that welcomes all interested members.Method: Members attend two meetings monthly via phone/computer/WebEx. One meeting is a targeted working group that focuses on the following: 1. Symptomatic (PLwD), 2. Asymptomatic (PwRD), 3. Research, 4. Ethics/Healthcare Law, 5. Trainee/Mentorship. These discussion groups hear from and present to stakeholders (PLwD/PwRD/caregivers, professional organizations, companies) to solicit feedback on the efficacy of their efforts. Members also attend a monthly “all hands” meeting where they receive updates from other groups and hear presentations on emerging research and resources.Result: The advisory group is composed of 104 members who represent advocacy/stakeholders (21%, e.g. professional organization representatives, (PLwD/PwRD/caregivers, FDA), academia (78%, e.g. university, funders, foundations), and healthcare law (1%). Professions include geneticists, genetic counsellors, researchers, clinicians, ethicists, and lawyers. Motivations for joining include improving communication in research and clinical contexts, mitigating potential negative impacts (e.g.emotional distress or discrimination), and protecting rights to know. Topics have included DTC genomics, the impact of APOE disclosure, genetics and personalized medicine, ecological momentary assessment of response to disclosure, and ethical issues in national and international research registries (EPAD). Activities included a survey on disclosure practices in NIA funded ADCs and collaborations with ADEAR. Stakeholders varied in concerns ranging from a need to protect patients from disclosure to a need to protect the right of access.Conclusion: Membership is increasing and is engaging diverse specialties and stakeholders who provide education and consultation around communication and use of genetic and biomarkers related to dementia. The group structure and inclusion of members from multiple organizations supports open and free collaboration. Future efforts will be developing structured education for stakeholders and publications.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S10)
Open AccessThe formation of the advisory group on risk evaluation education for dementia
Background: When and how to communicate effectively the results of genetic and biomarker based prediction, detection, and quantification of the brain substrates of dementia involve important ethical and legal issues critical for precision medicine. The urgency of the issue has increased as People Living with Dementia (PLwD) and with Risk for Dementia (PwRD) can access direct to consumer genetic testing, amyloid targeting drugs, and clinical amyloid PET scans. To address the need for effective dissemination and consultation, an advisory group was convened that welcomes all interested members.Method: Members attend two meetings monthly via phone/computer/WebEx. One meeting is a targeted working group that focuses on the following: 1. Symptomatic (PLwD), 2. Asymptomatic (PwRD), 3. Research, 4. Ethics/Healthcare Law, 5. Trainee/Mentorship. These discussion groups hear from and present to stakeholders (PLwD/PwRD/caregivers, professional organizations, companies) to solicit feedback on the efficacy of their efforts. Members also attend a monthly “all hands” meeting where they receive updates from other groups and hear presentations on emerging research and resources.Result: The advisory group is composed of 104 members who represent advocacy/stakeholders (21%, e.g. professional organization representatives, (PLwD/PwRD/caregivers, FDA), academia (78%, e.g. university, funders, foundations), and healthcare law (1%). Professions include geneticists, genetic counsellors, researchers, clinicians, ethicists, and lawyers. Motivations for joining include improving communication in research and clinical contexts, mitigating potential negative impacts (e.g.emotional distress or discrimination), and protecting rights to know. Topics have included DTC genomics, the impact of APOE disclosure, genetics and personalized medicine, ecological momentary assessment of response to disclosure, and ethical issues in national and international research registries (EPAD). Activities included a survey on disclosure practices in NIA funded ADCs and collaborations with ADEAR. Stakeholders varied in concerns ranging from a need to protect patients from disclosure to a need to protect the right of access.Conclusion: Membership is increasing and is engaging diverse specialties and stakeholders who provide education and consultation around communication and use of genetic and biomarkers related to dementia. The group structure and inclusion of members from multiple organizations supports open and free collaboration. Future efforts will be developing structured education for stakeholders and publications.